Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 24, 2024; 15(10): 1342-1350
Published online Oct 24, 2024. doi: 10.5306/wjco.v15.i10.1342
Hypofractionated and intensity-modulated radiotherapy combined with systemic therapy in metastatic hepatocellular carcinoma: A case report
Qiu-Qiu Chen, Chun-Qiao Chen, Jin-Kun Liu, Ming-Yue Huang, Min Pan, Hui Huang
Qiu-Qiu Chen, Chun-Qiao Chen, Jin-Kun Liu, Ming-Yue Huang, Min Pan, Hui Huang, Department of Oncology, People’s Hospital of Guilin, Guilin 541002, Guangxi Zhuang Autonomous Region, China
Co-first authors: Qiu-Qiu Chen and Chun-Qiao Chen.
Author contributions: Chen QQ and Huang H designed the research; Chen QQ, Chen CQ, Liu JK and Pan M performed the research; Liu JK, Huang MY and Pan M analyzed the data; Chen QQ, Chen CQ and Huang H wrote the paper. Chen QQ and Chen CQ contributed equally to this work as co-first authors.
Supported by Guangxi Guilin Science and Technology Fund, No. 20220139-9-8.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Huang, MD, Doctor, Department of Oncology, People’s Hospital of Guilin, No. 12 Wenming Road, Guilin 541002, Guangxi Zhuang Autonomous Region, China. huanghui25002@163.com
Received: April 8, 2024
Revised: August 16, 2024
Accepted: August 21, 2024
Published online: October 24, 2024
Processing time: 174 Days and 3.1 Hours
Core Tip

Core Tip: We report a 41-year-old man diagnosed with metastatic hepatocellular carcinoma (HCC) (T3N1M1 stage IVB), and discuss its imaging and hypofractionated and intensity-modulated radiotherapy combined with systemic therapy. The treatment showed good efficacy. The patient survived for 18 months without disease progression and stable disease persisted for > 38 months. These findings demonstrated that targeted therapy and immunotherapy followed by hypofractionated and intensity-modulated radiotherapy is a promising treatment regimen for advanced metastatic HCC, which is safe and controllable.